Drug intelligence / Profile preview

PD-1 antibody coexpression CD19-targeted CAR-T cells

Development stage: Unknown
Lead developer: Union Hospital of Huazhong University of Science and Technology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

PD-1 antibody coexpression CD19-targeted CAR-T cells is an investigational, genetically engineered autologous chimeric antigen receptor (CAR) T-cell therapy under development by the Institute of Hematology at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. This cell therapy is designed to target CD19-expressing B-cell malignancies while simultaneously co-expressing a programmed cell death protein 1 (PD-1) blocking antibody. By locally secreting or expressing the anti-PD-1 antibody, these CAR-T cells aim to disrupt the immunosuppressive PD-1/PD-L1 signaling pathway within the tumor microenvironment, thereby preventing T-cell exhaustion and enhancing the persistence and antitumor efficacy of the CAR-T cells. It is being evaluated in clinical trials for the treatment of relapsed or refractory B-cell lymphoma.

Other names: PD-1 antibody coexpressing CD19 CAR-T cellsPD1 antibody coexpressing CD19 CAR-T cellsPD 1 antibody coexpressing CD19 CAR-T cellsPD-1 antibody-coexpressing CD19 CAR-T cellsPD1 antibody-coexpressing CD19 CAR-T cellsPD 1 antibody-coexpressing CD19 CAR-T cellsPD-1 antibody-coexpressing CD19-directed CAR-T cellsPD1 antibody-coexpressing CD19-directed CAR-T cellsPD 1 antibody-coexpressing CD19-directed CAR-T cellsPD-1 antibody-coexpressing CD19-targeted CAR-T cellsPD1 antibody-coexpressing CD19-targeted CAR-T cellsPD 1 antibody-coexpressing CD19-targeted CAR-T cells

Targets

CD19 (B lymphocyte antigen CD19)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on PD-1 antibody coexpression CD19-targeted CAR-T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PD-1 antibody coexpression CD19-targeted CAR-T cells.

Explore the full profile